Sep 1 2009
BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) announces that its subsidiary BioSyent Pharma Inc. has signed an exclusive product development, supply and distribution agreement with a new partner for a new product under its Hospital Products Division. The product will be launched after Health Canada approval. This agreement represents the second new partner, with whom BioSyent Pharma has signed an agreement in the last two months.
BioSyent Inc. continues to concentrate on its pharmaceutical strategy to source products that have been successfully developed and proven to be safe and effective; manage these products through the regulatory process and product registration (approval); and once approved, market these products in Canada. These pharmaceuticals will compete in both the branded and generic market segments and will not require further product development investment other than regulatory costs.
BioSyent Inc. is a publicly traded specialty pharmaceutical company whose wholly owned subsidiary, BioSyent Pharma Inc., sources, acquires or in-licences pharmaceutical products and markets these products in Canada. Wholly owned BioSyent subsidiary Hedley Technologies Ltd. operates the company's legacy business marketing bio and health friendly non-chemical insecticides. BioSyent common shares are listed for trading on the TSX Venture Exchange (TSXV) under the symbol RX.
xhttp://www.biosyent.com/index.php?show=page&cid=170
Researchers uncover key mechanisms of CRISPR gene editing